Fresenius Kabi and Formycon have announced a global licensing deal for the FYB202 proposed biosimilar to Stelara (ustekinumab) being developed by Formycon.
The deal adds to Kabi’s growing interests in biosimilars, with the German generics giant indicating that it would gain “exclusive rights to commercialize the proposed ustekinumab biosimilar product in key global markets,” with “semi-exclusive commercialization rights for